Every time your cult leader comes out and calls me this and that, the stock tanks.
macclown----and the stock dropped from 16.54 to 14.50---
macturd-----the stock dropped from 12+ to where it is right now---
I didn't say they shorted the stock 'YET'. Do you have problem comprehending???.
And who said BlackRock bought 3M shares @15 when Achillion, on their latest Filing didn't provide a Price nor the Number of shares sold!LMAO
I lost my 8 ball otherwise I would have held on to my shorts averaging 16.3933 on 1/26. Discipline is Discipline!LOL
CIGNA SIGNS AGREEMENT WITH GILEAD TO IMPROVE AFFORDABILITY OF HEPATITIS C TREATMENT FOR CUSTOMERS AND CLIENTS
04 February 2015
Improving customers' health at the most competitive pricing benefits all stakeholders
Harvoni is the only Cigna preferred hepatitis C drug treatment for genotype 1
True in the case for Gilead but for a highly spec stock like ACHN, it doesn't take much fro a Dump. Having BlackRock on board is like holding a 2 edge knife. These guys are the worst in turn around rate. They aren't afraid to sell at first sign of trouble the short the heck out of the same stock to make their money back. Volume always precedes price action!
IBB is up 4.60 points, the stock couldn't even move. Yesterday, you could lay blame partly from the Indexes rotation or Gilead or Merck. What is the excuse today?
You people here are counting chicks when the mother hen is still a 5 month old pullet!LOL
The IND needs to be filed and accepted by the FDA first. Today Merck lost its 'Breakthrough Status' on their Protease Inhibitor + NS5A has all the implication the FDA would not allow Achillion to further test Sovaprevir aka 1625 beyond the 200 mg. This stock has more room to fall.
Preaching to the wrong Choir here. Funny thing for Magnam_pi to say this is a concerted effort to push the price down so their buddies can accumulate....Dumber than a Lava Rock!LOL
Your Logic is so flawed which I don't know whether to laugh at you and Pity your Ignorance.
1. Achillion only finished POC of 3422 for 14 days and need to go up to the 700 mg dose.
Even which that high dosage; 3 out of 6 achieved undetectable HCV RNA at day 14.
2. Not a word from them since December of 2014 regarding the Filing for an IND with the FDA.
3. Gilead is testing their second generation of NS5B Nucleotide/side Polymerase. Early results indicate the compound is more Potent than Sovaldi for a short duration of 6 weeks aiming at the hard to treat population and the Cirrhotic.
I bet you didn't know that....what 'Greymatter' if you have any left!LMAO.
Take time to weed through all his posting then tell me why I wouldn't bother to instruct nor debate. Beating on a dead horse about SVR8, 10 and 12 while purposely ignoring what is behind the high cure rate. Until this Company comes out with their own in house combo testing; one just could not attribute and take all credits while using Gilead's Sovaldi like many others have done so. I could #$%$ and on but as long as the folks here are still grasping at straws hoping and praying that Gilead would buy this company management included. It's not going to happen. Little they know Gilead is testing in a phase 2 their newest NS5B Nuc and it's more potent than Sovaldi.
This is the easiest short there is. People really don't know how to read the Filling. First The Public Offering is set at 8.75 and is expected to bring in 87.5 Millions to ZIOP. A Huge But is ' before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM.' Unreal some are chasing the stock.